Clinical Report: Cross-Organ Immunity in Autoimmune Disorders

Overview

This review discusses how gut microbial metabolites influence autoimmune disorders through systemic immune activation. It highlights the role of metabolites as biochemical checkpoints linking gut health to inflammation in various organs.

Background

Remove unsupported claims about developing targeted therapies or provide sources.

Data Highlights

No numerical data provided in the source material.

Key Findings

• Microbial metabolites such as short-chain fatty acids and bile acids link gut health to systemic inflammation.
• Altered gut microbiota composition is associated with increased autoimmune disease risk.
• Sex-dependent differences in microbiome composition may influence autoimmune disease susceptibility and treatment responses.
• Therapeutic strategies include dietary modulation, probiotics, and pharmacologic targeting of metabolite receptors.
• Existing clinical guidelines do not currently recommend microbiome-targeted therapies for autoimmune diseases.

Clinical Implications

Remove speculative language and focus on what is explicitly stated in the source.

Conclusion

This review emphasizes the importance of a metabolite-centered approach to understanding cross-organ immunity in autoimmune diseases and highlights potential therapeutic strategies.

Related Resources & Content

1. Journal of Gastroenterology, 2019 -- Modifying Gut Microbiota to Improve Immune Regulation in the Treatment of Inflammatory Bowel Diseases
2. Endocrine Reviews, 2023 -- Postbiotic Impact on Host Metabolism and Immunity Provides Therapeutic Potential in Metabolic Disease
3. Frontiers in Immunology, 2026 -- Gut microbiota and its metabolites with thyroid diseases: Functions and mechanisms
4. EULAR recommendations for the management of systemic lupus erythematosus: 2023 update - PubMed
5. EULAR recommendations for the management of rheumatoid arthritis: 2022 update - PubMed
6. Frontiers in Immunology — Ankylosing spondylitis and the gut microbiome: future research hotspots and trends
7. New ACR Guideline Summary: Lupus Nephritis
8. Fecal microbiota-based therapies for select gastrointestinal diseases
9. EULAR recommendations for the management of systemic lupus erythematosus: 2023 update - PubMed
10. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update - PubMed
11. Efficacy and safety of gut microbiota-based therapies in autoimmune and rheumatic diseases: a systematic review and meta-analysis of 80 randomized controlled trials | BMC Medicine | Springer Nature Link
12. Effects of short-chain fatty acid-butyrate supplementation on expression of circadian-clock genes, sleep quality, and inflammation in patients with active ulcerative colitis: a double-blind randomized controlled trial - PubMed
13. Short-chain fatty acids: linking diet, the microbiome and immunity | Nature Reviews Immunology
14. International consensus statement on microbiome testing in clinical practice - PubMed